A framework for assessment of adverse events occurring in psychedelic-assisted therapies
- 31 July 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (8) , 690-700
Abstract
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A multidisciplinary working group of experts involved in PAT pooled formally and informally documented AEs observed through research experience and published literature. This information was integrated with (a) current standards and practices for AE reporting in pharmacotherapy and psychotherapy trials and (b) published findings documenting post-acute dosing impacts of psychedelics on subjective states, meaning, and psychosocial health variables, to produce a set of AE constructs important to evaluate in PAT as well as recommended methods and time frames for their assessment and monitoring. Correspondence between identified potential AEs and current standards for AE assessment was examined, including the extent of coverage of identified AE constructs by 25 existing measures used in relevant research. Results: Fifty-four potential AE terms warranting systematized assessment in PAT were identified, defined, and categorized. Existing measures demonstrated substantial gaps in their coverage of identified AE constructs. Recommendations were developed for how to assess PAT AEs (including patient, clinician, and informant reports), and when to assess over preparation, dosing session, integration, and follow-up. Application of this framework is demonstrated in a preliminary assessment protocol (available in the supplement). Conclusions: This assessment framework addresses the need to capture post-acute dosing AEs in PAT, accounting for its pharmacotherapy and psychotherapy components, as well as documented impacts of psychedelics on worldviews and spirituality.Keywords
All Related Versions
This publication has 73 references indexed in Scilit:
- Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted TherapiesJAMA Psychiatry, 2023
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research LandscapeJAMA Psychiatry, 2023
- Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019Addictive Behaviors Reports, 2022
- When Psychotherapy Fails2022
- Neuropharmacology of N,N-dimethyltryptamineBrain Research Bulletin, 2016
- Religion as problem, religion as solution: religious buffers of the links between religious/spiritual struggles and well-being/mental healthQuality of Life Research, 2015
- LSD enhances suggestibility in healthy volunteersPsychopharmacology, 2014
- The Thalidomide Disaster, Lessons from the Past2012
- How to Define, Find and Classify Side Effects in Psychotherapy: From Unwanted Events to Adverse Treatment ReactionsClinical Psychology & Psychotherapy, 2012
- Imagery vividness and perceived anxious arousal in prolonged exposure treatment for PTSDJournal of Traumatic Stress, 2004